[{"data":1,"prerenderedAt":23},["ShallowReactive",2],{"notifications-general-it":3,"compound-CBT-it":4},"A causa delle vacanze estive, il laboratorio seguirà un orario modificato dal 22 luglio al 9 agosto 2026. I risultati delle analisi saranno disponibili entro 7-10 giorni dal ricevimento del campione. Grazie per la comprensione.",{"name":5,"shortname":6,"synonyms":7,"cas":8,"molMass":9,"pubchemLink":10,"structure":11,"important":12,"synthetic":13,"compoundClass":14,"asociationImage":17,"summarySet":18,"compoundEffectSet":22},"Cannabicitran","CBT","CBTC, (6aα,9β,10aα)-6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-1,9-epoxy-6H-dibenzo[b,d]pyran","31508-71-1",314.5,"https:\u002F\u002Fpubchem.ncbi.nlm.nih.gov\u002Fcompound\u002FCannabicitran","science\u002Fstructures\u002FCBT.png",true,false,{"id":15,"description":16},"2","Cannabinoids","",[19],{"summaryText":20,"language":21},"\u003Cp>Cannabicitran (CBT) is naturally found in hemp, albeit in rare quantities. It has demonstrated the ability to reduce intraocular pressure in rabbit tests, suggesting it may have potential use in managing conditions like glaucoma.The reduction in intraocular pressure is believed to be due to Cannabicitran's agonist activity at the NAGly receptor (GPR18), a target for many structurally related cannabinoids. \u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",null,[],1785925854282]